DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Crohn's Disease

Intervention: Infliximab (Biological)

Phase: N/A

Status: Completed

Sponsored by: Merck Sharp & Dohme Corp.

Summary

The aim of this study is to quantify how infliximab therapy is being used in the UK and the consequent impact on health care resources, which will help to inform budget holders and payers on the costs associated with the treatment of Crohn's Disease.

Clinical Details

Official title: A UK Retrospective Audit of Patients With Crohn's Disease Treated With Infliximab

Study design: Observational Model: Case-Only, Time Perspective: Retrospective

Primary outcome:

Mean Cost Per Participant of Consultations With Health Care Providers (HCPs)

Mean Cost Per Participant of Elective Surgical Procedures

Mean Cost Per Participant Due to Non-elective/Emergency Inpatient Admissions

Mean Cost Per Participant for Admissions for Day Case Surgery

Mean Cost Per Participant for All Hospitalizations

Mean Cost Per Participant of Accident and Emergency (A&E) Visits

Mean Cost Per Participant for Crohns-related Medications

Mean Cost Per Participant for Diagnostic Tests During Planned Outpatient Consultations

Detailed description: All interested hospital physicians across the UK who prescribe infliximab as part of their treatment of Crohn's Disease patients. will be included. It is assumed that the physician population will consist primarily of gastroenterologists, though general physicians (hospital-based) with an interest in Crohn's Disease may also be included.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of Crohn's Disease.

- Over the age of 18 years.

- Must have received the first infusion of infliximab on or after 1st January 2003

(when the maintenance therapy license was granted).

- Must have received at least one infusion of infliximab.

- A minimum of 12 months data prior to, and 24 months data post infliximab exposure

should be available in the medical records.

- Must have been under the care of the participating center for the entirety of the

study period. Exclusion Criteria:

- Should not have been involved in any clinical trial during the observational period

(ie, a minimum of 12 months before and 24 months after first receiving infliximab).

- Should not have received any biologic therapy prior to infliximab.

Locations and Contacts

Additional Information

Starting date: February 2010
Last updated: June 8, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017